Optimization of human immunodeficiency virus gag expression by newcastle disease virus vectors for the induction of potent immune responses.
about
Newcastle Disease Virus as a Vaccine Vector for Development of Human and Veterinary VaccinesExploiting tRNAs to Boost VirulenceComparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vectorHuman immunodeficiency virus vaccine an update.Development of replication-competent viral vectors for HIV vaccine delivery.Experimental infection of mice with avian paramyxovirus serotypes 1 to 9.Unique type I interferon responses determine the functional fate of migratory lung dendritic cells during influenza virus infection.Recombinant varicella vaccines induce neutralizing antibodies and cellular immune responses to SIV and reduce viral loads in immunized rhesus macaques.Newcastle disease virus expressing a dendritic cell-targeted HIV gag protein induces a potent gag-specific immune response in mice.Comparison of Heterologous Prime-Boost Strategies against Human Immunodeficiency Virus Type 1 Gag Using Negative Stranded RNA VirusesEvaluation of the replication, pathogenicity, and immunogenicity of avian paramyxovirus (APMV) serotypes 2, 3, 4, 5, 7, and 9 in rhesus macaquesEvaluation of the Newcastle disease virus F and HN proteins in protective immunity by using a recombinant avian paramyxovirus type 3 vector in chickens.A host-restricted viral vector for antigen-specific immunization against Lyme disease pathogen.T-cell Epitopes Identified by BALB/c Mice Immunized with Vaccinia Expressing HIV-1 Gag lie within immunodominant Regions Recognized by HIV-infected Indian Patients.Newcastle disease virus expressing human immunodeficiency virus type 1 envelope glycoprotein induces strong mucosal and serum antibody responses in Guinea pigsMucosal Immunization with Newcastle Disease Virus Vector Coexpressing HIV-1 Env and Gag Proteins Elicits Potent Serum, Mucosal, and Cellular Immune Responses That Protect against Vaccinia Virus Env and Gag Challenges.Attenuated influenza virus construct with enhanced hemagglutinin protein expressionEnhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.Immunization of cattle with recombinant Newcastle disease virus expressing bovine herpesvirus-1 (BHV-1) glycoprotein D induces mucosal and serum antibody responses and provides partial protection against BHV-1.Vaccinia and influenza A viruses select rather than adjust tRNAs to optimize translation.Recombinant lentogenic Newcastle disease virus expressing Ebola virus GP infects cells independently of exogenous trypsin and uses macropinocytosis as the major pathway for cell entry.Chimeric bovine/human parainfluenza virus type 3 expressing respiratory syncytial virus (RSV) F glycoprotein: effect of insert position on expression, replication, immunogenicity, stability, and protection against RSV infection.RNA-based viral vectors.HIV-1 vaccine immunogen design strategies.Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeuticsRecombinant Newcastle disease virus-vectored vaccines against human and animal infectious diseases.Rescue of recombinant Newcastle disease virus from cDNA.Apoptin enhances the oncolytic properties of Newcastle disease virus.Glycoprotein interactions in paramyxovirus fusion.Newcastle disease virus vectored vaccines as bivalent or antigen delivery vaccines.Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate.Role of untranslated regions in regulation of gene expression, replication, and pathogenicity of Newcastle disease virus expressing green fluorescent proteinParainfluenza virus 5-vectored vaccines against human and animal infectious diseases.A Recombinant Newcastle Disease Virus (NDV) Expressing S Protein of Infectious Bronchitis Virus (IBV) Protects Chickens against IBV and NDV
P2860
Q26744220-9FD30F6D-B815-4DA4-8AF9-C948B3662680Q26770055-7F4A0EFD-300C-4BA0-83FE-043DEBB05682Q28533970-0D919DC6-2B42-48C0-946D-9B99072B7F4FQ30432382-798367CB-8D0B-44CA-94BF-8963F0546CE9Q33694226-46913884-C489-482A-B1A7-B925CE847D25Q33828508-0A6DC15B-E26D-4820-A847-B3143FAC71D8Q34071375-DCFC2532-4E5B-4796-8810-3B98C4BCCFB0Q34701202-5BBE460E-C3E9-498F-92EE-FE35621AE5B5Q34741882-17AAF06A-E142-4682-9F4F-80C241C7B03CQ34806497-55E5397F-FC99-4A36-8CC3-437E87737269Q35018292-DB8346CD-C394-46C9-A817-26A3283E90E2Q35077454-A77B750F-DD2B-4608-A993-098CE6ADC6CDQ35112976-D02F0847-BF7F-4DAB-BC90-8F1D7B4761A7Q35183962-F9F78EF8-3733-45C0-819A-809154B78E45Q35275117-1EB7F042-BBC7-4383-9FAE-6CBE2529D172Q35883750-53AFB74E-DD69-411F-9084-704D65C50E77Q35943504-6FF03468-D17A-47D3-94B9-9F1350FFED91Q35973617-ACA8974D-C5D3-4706-BC7B-CACBB6A6F601Q36190495-6B1AF35D-A4F0-4FB8-9A92-7BBB1350BDDAQ36580893-5296C9D7-8AC7-4D4A-898E-0911B107FB58Q37304963-709BB537-6D7E-489A-AFFC-24968FF5223DQ37713874-76084650-7304-4B27-9BC6-4720C1331EFAQ38266413-42DAB32D-464C-46E6-A5E3-5B1E74056F8FQ38330424-04DB304D-EFCA-4988-99C1-D8063C529AD5Q38363535-9D583E41-3492-4E7D-9EE2-CEDE2AE5194BQ38559266-EA72EB53-7EED-438B-933F-F271B8F1F671Q39074984-9AB3E0CF-621F-4967-9202-58BD6106D06BQ39484906-84D0B66A-C8FE-4C50-915B-B02C14FAA36CQ39900113-0D52C5D3-924C-4799-9309-7690D172878EQ40095159-937306F0-2DFD-498D-8FE2-03C90493C505Q40187606-76142603-D727-4F14-ACAF-56A1FEC7EE28Q42092096-1674861B-9532-4BBE-869B-DEC1DEFB5F75Q47556502-04345D23-C153-401B-BFA6-6FC62C746E83Q58791018-147F5FD1-CDD4-469D-9843-3DED72B2067C
P2860
Optimization of human immunodeficiency virus gag expression by newcastle disease virus vectors for the induction of potent immune responses.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Optimization of human immunode ...... on of potent immune responses.
@en
Optimization of human immunode ...... on of potent immune responses.
@nl
type
label
Optimization of human immunode ...... on of potent immune responses.
@en
Optimization of human immunode ...... on of potent immune responses.
@nl
prefLabel
Optimization of human immunode ...... on of potent immune responses.
@en
Optimization of human immunode ...... on of potent immune responses.
@nl
P2093
P2860
P356
P1433
P1476
Optimization of human immunode ...... on of potent immune responses.
@en
P2093
Bruno Moltedo
Elena Carnero
Thomas Moran
Wenjing Li
P2860
P304
P356
10.1128/JVI.01443-08
P407
P577
2008-11-12T00:00:00Z